Gemini Therapeutics Announces Corporate Restructuring to Prioritize Late-Stage Clinical Development of GEM103 for Geographic AtrophyBusiness Wire • 10/05/21
Gemini Therapeutics Announces Presentation of Preclinical Data at the 13th International Conference on Complement TherapeuticsBusiness Wire • 09/10/21
Gemini Therapeutics Announces Presentation of Previously Released Data from Its Ongoing Phase 2a Study of GEM103 at EURETINA 2021 VirtualBusiness Wire • 09/09/21
Gemini Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment ConferenceBusiness Wire • 09/07/21
Is the Options Market Predicting a Spike in Gemini Therapeutics (GMTX) Stock?Zacks Investment Research • 08/30/21
Gemini Therapeutics Announces Presentation of Previously Released Data from Its Ongoing Phase 2a Study of GEM103 at Clinical Trials at the SummitBusiness Wire • 08/30/21
Gemini Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business UpdateBusiness Wire • 08/12/21
Gemini Therapeutics to Participate in the H.C. Wainwright Ophthalmology ConferenceBusiness Wire • 08/10/21
Gemini Therapeutics Announces Initial Data From Its Ongoing Phase 2a Study of GEM103 in Patients With Geographic Atrophy Secondary to Dry Age-Related Macular DegenerationBusiness Wire • 06/22/21
Gemini Therapeutics to Participate in the Jefferies Virtual Healthcare ConferenceBusiness Wire • 05/26/21
Gemini Therapeutics Reports First Quarter 2021 Financial Results and Provides Business UpdateBusiness Wire • 05/13/21
Gemini Therapeutics Completes Enrollment in Phase 2a Study of GEM103 as an Add-On to Anti-VEGF Therapy for the Treatment of Wet AMD Patients at Risk for Progressive Vision Loss Due to Macular AtrophyBusiness Wire • 05/13/21
Gemini Therapeutics Announces Appointment of Georges Gemayel, Ph.D. as Chair of Board of DirectorsBusiness Wire • 05/03/21
Gemini Therapeutics Announces Presentation of Preclinical Data at 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual MeetingBusiness Wire • 05/01/21
Gemini Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)Business Wire • 04/13/21
Gemini Therapeutics Reports Full Year 2020 Financial Results and Provides Business UpdateBusiness Wire • 03/29/21
Gemini Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare ConferenceBusiness Wire • 02/19/21
Gemini Therapeutics Completes 60 Patients Enrollment In Lead Candidate Mid-Stage Study In Dry AMDBenzinga • 02/10/21
Gemini Therapeutics Completes Enrollment in Phase 2a Trial of GEM103 in Dry Age-Related Macular Degeneration (AMD) in Patients with High-Risk Genetic VariantsBusiness Wire • 02/10/21